These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22525883)

  • 1. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol.
    Hébuterne X; Lémann M; Bouhnik Y; Dewit O; Dupas JL; Mross M; D'Haens G; Mitchev K; Ernault É; Vermeire S; Brixi-Benmansour H; Moreels TG; Mary JY; Marteau P; Colombel JF
    Gut; 2013 Feb; 62(2):201-8. PubMed ID: 22525883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.
    Colombel JF; Sandborn WJ; Allez M; Dupas JL; Dewit O; D'Haens G; Bouhnik Y; Parker G; Pierre-Louis B; Hébuterne X
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):423-31.e1. PubMed ID: 24184736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.
    Ordás I; Rimola J; Rodríguez S; Paredes JM; Martínez-Pérez MJ; Blanc E; Arévalo JA; Aduna M; Andreu M; Radosevic A; Ramírez-Morros AM; Pinó S; Gallego M; Jauregui-Amezaga A; Ricart E; Panés J
    Gastroenterology; 2014 Feb; 146(2):374-82.e1. PubMed ID: 24177375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
    N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A
    Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.
    Sandborn WJ; Abreu MT; D'Haens G; Colombel JF; Vermeire S; Mitchev K; Jamoul C; Fedorak RN; Spehlmann ME; Wolf DC; Lee S; Rutgeerts P
    Clin Gastroenterol Hepatol; 2010 Aug; 8(8):688-695.e2. PubMed ID: 20451663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study.
    Sandborn WJ; Lee SD; Randall C; Gutierrez A; Schwartz DA; Ambarkhane S; Kayhan C; Pierre-Louis B; Schreiber S; Lichtenstein GR
    Aliment Pharmacol Ther; 2014 Oct; 40(8):903-16. PubMed ID: 25146586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
    Schoepfer AM; Vavricka SR; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Seibold F; Straumann A; Michetti P;
    Inflamm Bowel Dis; 2010 Jun; 16(6):933-8. PubMed ID: 20014021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
    Danese S; Sandborn WJ; Colombel JF; Vermeire S; Glover SC; Rimola J; Siegelman J; Jones S; Bornstein JD; Feagan BG
    Gastroenterology; 2019 Oct; 157(4):1007-1018.e7. PubMed ID: 31279871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.
    Smolen JS; Emery P; Ferraccioli GF; Samborski W; Berenbaum F; Davies OR; Koetse W; Purcaru O; Bennett B; Burkhardt H
    Ann Rheum Dis; 2015 May; 74(5):843-50. PubMed ID: 24431394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Certolizumab pegol for the treatment of Crohn's disease.
    Sandborn WJ; Feagan BG; Stoinov S; Honiball PJ; Rutgeerts P; Mason D; Bloomfield R; Schreiber S;
    N Engl J Med; 2007 Jul; 357(3):228-38. PubMed ID: 17634458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.
    Vavricka SR; Schoepfer AM; Bansky G; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Scharl M; Seibold F; Straumann A; Michetti P;
    Inflamm Bowel Dis; 2011 Jul; 17(7):1530-9. PubMed ID: 21674709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease.
    Augustine JM; Lee JK; Armstrong EP
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):599-609. PubMed ID: 25209304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
    Lichtenstein GR; Thomsen OØ; Schreiber S; Lawrance IC; Hanauer SB; Bloomfield R; Sandborn WJ;
    Clin Gastroenterol Hepatol; 2010 Jul; 8(7):600-9. PubMed ID: 20117244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Certolizumab pegol for induction of remission in Crohn's disease.
    Yamazaki H; So R; Matsuoka K; Kobayashi T; Shinzaki S; Matsuura M; Okabayashi S; Kataoka Y; Tsujimoto Y; Furukawa TA; Watanabe N
    Cochrane Database Syst Rev; 2019 Aug; 8(8):CD012893. PubMed ID: 31476018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.
    Feagan BG; Reilly MC; Gerlier L; Brabant Y; Brown M; Schreiber S
    Aliment Pharmacol Ther; 2010 Jun; 31(12):1276-85. PubMed ID: 20298497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.
    Schreiber S; Colombel JF; Bloomfield R; Nikolaus S; Schölmerich J; Panés J; Sandborn WJ;
    Am J Gastroenterol; 2010 Jul; 105(7):1574-82. PubMed ID: 20234346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease.
    Rutgeerts P; Schreiber S; Feagan B; Keininger DL; O'Neil L; Fedorak RN;
    Int J Colorectal Dis; 2008 Mar; 23(3):289-96. PubMed ID: 18071721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.